Transition of European Cooperative Acute Stroke Study III Results to Clinical Practice: Ninety-Day Outcomes in a US Cohort [Brief Reports]
Conclusions—
For patients treated with intravenous tissue-type plasminogen activator 3 to 4.5 hours from onset in everyday practice in the United States, there is no evidence for increased risk or worse outcomes compared with standard treatment ≤3 hours.
Source: Stroke - Category: Neurology Authors: Cronin, C. A., Langenberg, P., Dutta, T. M., Kittner, S. J. Tags: Brief Reports Source Type: research
More News: Academia | Diabetes | Diabetes Mellitus | Endocrinology | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Statistics | Stroke | Study